Novel Mutation in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia

A Series of Three Cases

Nosrat Ghaemi, Martha Ghahraman, Mohammad Reza Abbaszadegan, Alireza Baradaran-Heravi, Rahim Vakili*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thiamine-responsive megaloblastic anemia (TRMA) is a clinical triad characterized by megaloblastic anemia, non-autoimmune diabetes mellitus, and sensory-neural hearing loss. Mutations in the thiamine transporter gene, solute carrier family 19, member 2 (SLC19A2), have been associated with TRMA. Three pediatric patients from a large consanguineous Iranian family with hyperglycemia, anemia, and hearing loss were clinically diagnosed with TRMA. In all three patients, TRMA was confirmed by direct sequencing of the SLC19A2 gene that revealed a novel missense homozygous mutation c.382 G>A (p.E128K). This mutation results in the substitution of glutamic acid to lysine at position 128 in exon 2 and was not detected in 200 control chromosomes. Thiamine therapy reversed the anemia and alleviated the hyperglycemia in all three patients. We recommend sequence analysis of the SLC19A2 gene in individuals with a clinical triad of diabetes mellitus, hearing loss, and anemia. The administration of thiamine ameliorates the megaloblastic anemia and the hyperglycemia in patients with TRMA.

Original languageEnglish
Pages (from-to)199-201
Number of pages3
JournalJournal of clinical research in pediatric endocrinology
Volume5
Issue number3
DOIs
Publication statusPublished - 2013

Keywords

  • Megaloblastic anemia
  • diabetes mellitus
  • hearing loss
  • SLC19A2
  • DIABETES-MELLITUS
  • SENSORINEURAL DEAFNESS
  • TRANSPORTER

Cite this

Novel Mutation in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia : A Series of Three Cases. / Ghaemi, Nosrat; Ghahraman, Martha; Abbaszadegan, Mohammad Reza; Baradaran-Heravi, Alireza; Vakili, Rahim.

In: Journal of clinical research in pediatric endocrinology, Vol. 5, No. 3, 2013, p. 199-201.

Research output: Contribution to journalArticle

@article{7c5df5f0818c4be4ad1974ddc6c4af44,
title = "Novel Mutation in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia: A Series of Three Cases",
abstract = "Thiamine-responsive megaloblastic anemia (TRMA) is a clinical triad characterized by megaloblastic anemia, non-autoimmune diabetes mellitus, and sensory-neural hearing loss. Mutations in the thiamine transporter gene, solute carrier family 19, member 2 (SLC19A2), have been associated with TRMA. Three pediatric patients from a large consanguineous Iranian family with hyperglycemia, anemia, and hearing loss were clinically diagnosed with TRMA. In all three patients, TRMA was confirmed by direct sequencing of the SLC19A2 gene that revealed a novel missense homozygous mutation c.382 G>A (p.E128K). This mutation results in the substitution of glutamic acid to lysine at position 128 in exon 2 and was not detected in 200 control chromosomes. Thiamine therapy reversed the anemia and alleviated the hyperglycemia in all three patients. We recommend sequence analysis of the SLC19A2 gene in individuals with a clinical triad of diabetes mellitus, hearing loss, and anemia. The administration of thiamine ameliorates the megaloblastic anemia and the hyperglycemia in patients with TRMA.",
keywords = "Megaloblastic anemia, diabetes mellitus, hearing loss, SLC19A2, DIABETES-MELLITUS, SENSORINEURAL DEAFNESS, TRANSPORTER",
author = "Nosrat Ghaemi and Martha Ghahraman and Abbaszadegan, {Mohammad Reza} and Alireza Baradaran-Heravi and Rahim Vakili",
year = "2013",
doi = "10.4274/Jcrpe.969",
language = "English",
volume = "5",
pages = "199--201",
journal = "Journal of clinical research in pediatric endocrinology",
issn = "1308-5727",
publisher = "GALENOS YAYINCILIK",
number = "3",

}

TY - JOUR

T1 - Novel Mutation in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia

T2 - A Series of Three Cases

AU - Ghaemi, Nosrat

AU - Ghahraman, Martha

AU - Abbaszadegan, Mohammad Reza

AU - Baradaran-Heravi, Alireza

AU - Vakili, Rahim

PY - 2013

Y1 - 2013

N2 - Thiamine-responsive megaloblastic anemia (TRMA) is a clinical triad characterized by megaloblastic anemia, non-autoimmune diabetes mellitus, and sensory-neural hearing loss. Mutations in the thiamine transporter gene, solute carrier family 19, member 2 (SLC19A2), have been associated with TRMA. Three pediatric patients from a large consanguineous Iranian family with hyperglycemia, anemia, and hearing loss were clinically diagnosed with TRMA. In all three patients, TRMA was confirmed by direct sequencing of the SLC19A2 gene that revealed a novel missense homozygous mutation c.382 G>A (p.E128K). This mutation results in the substitution of glutamic acid to lysine at position 128 in exon 2 and was not detected in 200 control chromosomes. Thiamine therapy reversed the anemia and alleviated the hyperglycemia in all three patients. We recommend sequence analysis of the SLC19A2 gene in individuals with a clinical triad of diabetes mellitus, hearing loss, and anemia. The administration of thiamine ameliorates the megaloblastic anemia and the hyperglycemia in patients with TRMA.

AB - Thiamine-responsive megaloblastic anemia (TRMA) is a clinical triad characterized by megaloblastic anemia, non-autoimmune diabetes mellitus, and sensory-neural hearing loss. Mutations in the thiamine transporter gene, solute carrier family 19, member 2 (SLC19A2), have been associated with TRMA. Three pediatric patients from a large consanguineous Iranian family with hyperglycemia, anemia, and hearing loss were clinically diagnosed with TRMA. In all three patients, TRMA was confirmed by direct sequencing of the SLC19A2 gene that revealed a novel missense homozygous mutation c.382 G>A (p.E128K). This mutation results in the substitution of glutamic acid to lysine at position 128 in exon 2 and was not detected in 200 control chromosomes. Thiamine therapy reversed the anemia and alleviated the hyperglycemia in all three patients. We recommend sequence analysis of the SLC19A2 gene in individuals with a clinical triad of diabetes mellitus, hearing loss, and anemia. The administration of thiamine ameliorates the megaloblastic anemia and the hyperglycemia in patients with TRMA.

KW - Megaloblastic anemia

KW - diabetes mellitus

KW - hearing loss

KW - SLC19A2

KW - DIABETES-MELLITUS

KW - SENSORINEURAL DEAFNESS

KW - TRANSPORTER

U2 - 10.4274/Jcrpe.969

DO - 10.4274/Jcrpe.969

M3 - Article

VL - 5

SP - 199

EP - 201

JO - Journal of clinical research in pediatric endocrinology

JF - Journal of clinical research in pediatric endocrinology

SN - 1308-5727

IS - 3

ER -